Abstract
Dextromethorphan 1 is an effective neuroprotectant in animal models of epilepsy and ischemia but showed side-effects during clinical trials limiting its potential use in a clinical setting. Here we describe the enantioselective and enantiospecific syntheses and the initial in vitro and in vivo biological evaluation of new hybrid structures between 1 and a previously disclosed alpha-amino amide anticonvulsant (3).
MeSH terms
-
Alanine / analogs & derivatives*
-
Alanine / chemical synthesis
-
Alanine / pharmacology
-
Animals
-
Anticonvulsants / chemical synthesis*
-
Anticonvulsants / pharmacology*
-
Benzylamines / chemical synthesis*
-
Benzylamines / pharmacology*
-
Brain / drug effects
-
Dextromethorphan / analogs & derivatives
-
Dextromethorphan / chemistry*
-
Inhibitory Concentration 50
-
Kinetics
-
Mice
-
Rats
Substances
-
Anticonvulsants
-
Benzylamines
-
Dextromethorphan
-
safinamide
-
Alanine